Literature DB >> 32350376

Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression.

Polona Novak1,2, Evgeny Klyuchnikov1, Ute-Marie von Pein1, Martina Güllstorf1, Maximilian Christopeit1, Francis Ayuk1, Maria Geffken3, Christine Wolschke1, Nicolaus Kröger4.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32350376     DOI： 10.1038/s41409-020-0912-7

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Guidelines for determination of the number of prior lines of therapy in multiple myeloma.

Authors:  S Vincent Rajkumar; Paul Richardson; Jesus F San Miguel
Journal:  Blood       Date:  2015-08-13       Impact factor: 22.113

2.  [Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation].

Authors:  Mayumi Hatsuse; Kyoko Taniguchi-Yoshihara; Shigeki Yagyu; Shin-ichi Fuchida; Akira Okano; Satoshi Murakami; Chihiro Shimazaki
Journal:  Rinsho Ketsueki       Date:  2015-04

3.  Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic hematopoietic SCT.

Authors:  E Palfreyman; K Song; S Nantel
Journal:  Bone Marrow Transplant       Date:  2013-02-18       Impact factor: 5.483

4.  Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

Authors:  M Sobh; M Michallet; G Gahrton; S Iacobelli; A van Biezen; S Schönland; E Petersen; N Schaap; F Bonifazi; L Volin; E Meijer; D Niederwieser; J El Cheikh; R Tabrizi; N Fegeux; J Finke; D Bunjes; J Cornelissen; H Einsele; B Bruno; M Potter; R Fanin; M Mohty; L Garderet; N Kröger
Journal:  Leukemia       Date:  2016-04-27       Impact factor: 11.528

5.  Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.

Authors:  Leo Rasche; Christoph Röllig; Gernot Stuhler; Sophia Danhof; Stephan Mielke; Goetz Ulrich Grigoleit; Lea Dissen; Lea Schemmel; Jan Moritz Middeke; Viktoria Rücker; Martin Schreder; Johannes Schetelig; Martin Bornhäuser; Hermann Einsele; Christian Thiede; Stefan Knop
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-31       Impact factor: 5.742

6.  CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.

Authors:  Evgeny Klyuchnikov; Jean El-Cheikh; Andreas Sputtek; Michael Lioznov; Boris Calmels; Sabine Furst; Christian Chabannon; Roberto Crocchiolo; Claude Lemarié; Catherine Faucher; Ulrike Bacher; Haefaa Alchalby; Thomas Stübig; Christine Wolschke; Francis Ayuk; Marie-Luise Reckhaus; Didier Blaise; Nicolaus Kröger
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-07       Impact factor: 5.742

7.  The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma.

Authors:  Henk M Lokhorst; Kalung Wu; Leo F Verdonck; Laurens L Laterveer; Niels W C J van de Donk; Marinus H J van Oers; Jan J Cornelissen; Anton V Schattenberg
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

8.  Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

Authors:  Gösta Gahrton; Simona Iacobelli; Bo Björkstrand; Ute Hegenbart; Astrid Gruber; Hildegard Greinix; Liisa Volin; Franco Narni; Angelo Michele Carella; Meral Beksac; Alberto Bosi; Giuseppe Milone; Paolo Corradini; Stefan Schönland; Kristina Friberg; Anja van Biezen; Hartmut Goldschmidt; Theo de Witte; Curly Morris; Dietger Niederwieser; Laurent Garderet; Nicolaus Kröger
Journal:  Blood       Date:  2013-03-12       Impact factor: 22.113

9.  Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

Authors:  Nicolaus Kröger; Anita Badbaran; Tatjana Zabelina; Francis Ayuk; Christine Wolschke; Haefaa Alchalby; Evgeny Klyuchnikov; Djordje Atanackovic; Georgia Schilling; Timon Hansen; Sabine Schwarz; Marion Heinzelmann; Silke Zeschke; Ulrike Bacher; Thomas Stübig; Boris Fehse; Axel R Zander
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-16       Impact factor: 5.742

10.  CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.

Authors:  Eric Smith; Sean M Devlin; Satyajit Kosuri; Evelyn Orlando; Heather Landau; Alex M Lesokhin; David J Chung; Hani Hassoun; Nikoletta Lendvai; Ola Landgren; Sergio Giralt; Ajai Chari; Sundar Jagannath; Guenther Koehne
Journal:  Biol Blood Marrow Transplant       Date:  2015-08-30       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.